<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735343</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20160057H</org_study_id>
    <nct_id>NCT02735343</nct_id>
  </id_info>
  <brief_title>The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine</brief_title>
  <acronym>Check</acronym>
  <official_title>The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine. A Multi-Center, Randomized, Double-Blind, Clinical Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mike O'Callaghan Military Hospital</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mike O'Callaghan Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are comparing Ketamine to prochlorperazinecompazine for benign headaches in the&#xD;
      ED. Subjects will be randomized into 1 of 2 groups. Group 1 will receive standard treatment&#xD;
      of prochlorperazinecompazine 10 mg IV along with diphenhydramine 25 mg IV. Group 2 (research&#xD;
      arm) will receive Ketamine 0.3 mg/kg along with ondansetron 4 mg IV. Subjects will be seen at&#xD;
      15, 30, 45, and 60 minutes post-intervention to obtain Heart Rate, Blood Pressure, Headache&#xD;
      severity, Nausea severity, Vomiting severity, Anxiety severity, and Restlessness severity. At&#xD;
      24-48 hours post intervention we will contact subjects and assess their pain and assess their&#xD;
      satisfaction with their migraine pain management as part of this study. Subjects'&#xD;
      participation will last up to 48 hours post headache.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening Visit:&#xD;
&#xD;
        -  Obtain signed Informed Consent Document and HIPAA Authorization (research-driven).&#xD;
&#xD;
        -  Record: Date of birth, age, phone number, gender, race, ethnicity, social security&#xD;
           number, name of standard of care rescue medications (over-the-counter and prescription),&#xD;
           current email address (to be used for scheduling only), height (in inches), weight (in&#xD;
           pounds), history of traumatic brain injury, concussion, or any mild to severe head&#xD;
           trauma, medication use. (research only)&#xD;
&#xD;
        -  Review past medical history in Armed Forces Health Longitudinal Technology Application&#xD;
           (AHLTA) or ESSENTRIS to verify the inclusion/exclusion criteria.&#xD;
&#xD;
        -  Women of childbearing potential will have a serum pregnancy test (5-10 milliliters&#xD;
           (mls), approximately 1-2 teaspoons of blood) (research-driven).&#xD;
&#xD;
      Visit 1:&#xD;
&#xD;
        -  Heart rate&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Headache severity via 100-mm VAS.&#xD;
&#xD;
        -  Nausea severity via 100-mm VAS.&#xD;
&#xD;
        -  Vomiting severity via 100-mm VAS.&#xD;
&#xD;
        -  Anxiety severity via 100-mm VAS.&#xD;
&#xD;
        -  Restlessness severity via 100-mm VAS.&#xD;
&#xD;
        -  Record type and amount of rescue medications (over-the-counter and prescription) use in&#xD;
           the past 7 days. (research only)&#xD;
&#xD;
        -  Subjects will be randomized by the pharmacy. We will use a random-number generator and&#xD;
           use blocking to ensure roughly equal sample sizes. Both subjects and investigators will&#xD;
           be blinded to the study group assignments. Subjects will be randomized by the pharmacy&#xD;
           into one of two groups (research-driven):&#xD;
&#xD;
             -  Group 1: Standard treatment arm (prochlorperazinecompazine 10 mg IV along with&#xD;
                diphenhydramine 25 mg IV)&#xD;
&#xD;
             -  Group 2: Research arm (Ketamine 0.3 mg/kg along with ondansetron 4 mg IV)&#xD;
&#xD;
                15 minutes post treatment:&#xD;
&#xD;
        -  Heart rate&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Headache severity via 100-mm VAS.&#xD;
&#xD;
        -  Nausea severity via 100-mm VAS.&#xD;
&#xD;
        -  Vomiting severity via 100-mm VAS.&#xD;
&#xD;
        -  Anxiety severity via 100-mm VAS.&#xD;
&#xD;
        -  Restlessness severity via 100-mm VAS.&#xD;
&#xD;
           30 minutes post treatment:&#xD;
&#xD;
        -  Heart rate&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Headache severity via 100-mm VAS.&#xD;
&#xD;
        -  Nausea severity via 100-mm VAS.&#xD;
&#xD;
        -  Vomiting severity via 100-mm VAS.&#xD;
&#xD;
        -  Anxiety severity via 100-mm VAS.&#xD;
&#xD;
        -  Restlessness severity via 100-mm VAS.&#xD;
&#xD;
           45 minutes post treatment:&#xD;
&#xD;
        -  Heart rate&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Headache severity via 100-mm VAS.&#xD;
&#xD;
        -  Nausea severity via 100-mm VAS.&#xD;
&#xD;
        -  Vomiting severity via 100-mm VAS.&#xD;
&#xD;
        -  Anxiety severity via 100-mm VAS.&#xD;
&#xD;
        -  Restlessness severity via 100-mm VAS.&#xD;
&#xD;
           60 minutes post treatment:&#xD;
&#xD;
        -  Heart rate&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Headache severity via 100-mm VAS.&#xD;
&#xD;
        -  Nausea severity via 100-mm VAS.&#xD;
&#xD;
        -  Vomiting severity via 100-mm VAS.&#xD;
&#xD;
        -  Anxiety severity via 100-mm VAS.&#xD;
&#xD;
        -  Restlessness severity via 100-mm VAS.&#xD;
&#xD;
      24-48 hours post treatment:&#xD;
&#xD;
        -  Subjects will be contacted either in-person or via phone and the following information&#xD;
           will be collected:&#xD;
&#xD;
             -  Subjects will be asked &quot;On a scale of 0-10, with 10 being the worst pain, what is&#xD;
                your current level of pain?&quot;&#xD;
&#xD;
             -  Subjects will be asked &quot;On a scale of 0 to 10, how satisfied were you with you're&#xD;
                the migraine pain management as part of this research study? (dissatisfied 0 - 10&#xD;
                very satisfied)&#xD;
&#xD;
        -  Subjects will be alerted to what group they were randomized into.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    only recruited 5 patients at this location&#xD;
  </why_stopped>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Standard treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Research arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compazine</intervention_name>
    <description>Compazine 10mg with diphenhydramine 25 mg IV</description>
    <arm_group_label>Standard treatment arm</arm_group_label>
    <other_name>prochlorperazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.3 mg/kg along with ondansetron 4 mg IV</description>
    <arm_group_label>Research arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE&#xD;
        IN ORDER TO PARTICIPATE IN THIS STUDY.&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Age 18 to 65 years who present to the ED with complaint of a headache&#xD;
&#xD;
          -  Temperature less than 100.4 F&#xD;
&#xD;
          -  Diastolic blood pressure less than 104 mm Hg&#xD;
&#xD;
          -  Normal neurologic exam and normal mental status&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Meningeal signs are present&#xD;
&#xD;
          -  Acute angle closure glaucoma is suspected&#xD;
&#xD;
          -  Head trauma within the previous two weeks&#xD;
&#xD;
          -  Lumbar puncture within the previous two weeks&#xD;
&#xD;
          -  Thunderclap (rapid) onset of the headache&#xD;
&#xD;
          -  Weight more than 150 kg or less than 40 kg&#xD;
&#xD;
          -  Known allergy to diphenhydramine&#xD;
&#xD;
          -  Known allergy to ondansetron. (Zofran)&#xD;
&#xD;
          -  Known allergy to Compazine&#xD;
&#xD;
          -  Known allergy to Ketamine&#xD;
&#xD;
          -  History of schizophrenia or bipolar disorder&#xD;
&#xD;
          -  History of intracranial hypertension&#xD;
&#xD;
          -  Is a prisoner&#xD;
&#xD;
          -  Patient declined informed consent&#xD;
&#xD;
          -  Non-English speaking patient&#xD;
&#xD;
          -  Attending provider excludes patient&#xD;
&#xD;
          -  Elderly patients with dementia&#xD;
&#xD;
          -  Patients with severe headaches that diminish their decision making capability will not&#xD;
             be able to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Pitotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mike O'Callaghan Federal Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mike O'Callaghan Federal Medical Center</name>
      <address>
        <city>Nellis Air Force Base</city>
        <state>Nevada</state>
        <zip>89191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mike O'Callaghan Military Hospital</investigator_affiliation>
    <investigator_full_name>JillClark</investigator_full_name>
    <investigator_title>Senior Research Associate/Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be shared with University Medical Center of Southern Nevada via a Cooperative Research and Development Agreement. They are conducing the same study under a different IRB.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

